Most active Roche Holding AG (ROG.SW) on SIX CHF338.30 30 Jan 2026: momentum to watch
ROG.SW stock finished the session at CHF 338.30 on SIX on 30 Jan 2026, with volume 1489237.00 putting Roche among the markets most active names. The share traded between CHF 335.80 and CHF 344.00, reflecting tight intraday range but strong relative interest versus average volume 1141438.00. Investors tracked a high PE of 29.56 and EPS 11.74, while headlines and sector flows drove a measured rotation into healthcare. We summarise the drivers, valuation, technicals, proprietary Meyka AI grade and a model forecast that frames short and medium term price paths.
ROG.SW stock intraday snapshot and market context
Roche Holding AG (ROG.SW) closed at CHF 338.30 on SIX with volume 1489237.00. The stock opened at CHF 342.30 and traded inside a day high CHF 344.00 and day low CHF 335.80. Year range sits at CHF 231.90 to CHF 355.10, and market cap is CHF 276322482371.00. Sector flows in Healthcare were positive year to date, supporting Roches status as a high-liquidity defensive name.
ROG.SW stock drivers and recent news
Price action followed mixed earnings commentary and diagnostic sales updates after Roches recent report on 29 Jan 2026, which showed stability in diagnostics but pressure in some pharma margins. Market coverage noted by Reuters and CNBC highlighted the companys scale and pipeline as central to investor attention source source. Macro demand for defensive healthcare names lifted trading volumes, making Roche one of the most active Swiss stocks on the day.
ROG.SW stock valuation, cash flow and dividends
Valuation metrics show a PE of 29.56 and EPS 11.74, with price averages 50-day CHF 326.85 and 200-day CHF 280.51. Free cash flow yield is 0.04555 and dividend per share is 9.70, equating to a dividend yield near 2.80%. Enterprise value to EBITDA is 24.26 and debt to equity stands at 1.21, highlighting a leveraged balance between investment in R&D and shareholder returns.
Technical view for ROG.SW stock
Momentum indicators show short-term strength: RSI 73.06 (overbought) and ADX 43.57 (strong trend). Bollinger upper band is 338.28, middle 322.94, lower 307.59, suggesting price sits near resistance. Average daily volume 1141438.00 versus todays 1489237.00 confirms above-average liquidity and trader interest. Technicals favour momentum trades but signal caution for new longs given overbought oscillators.
Meyka AI rates ROG.SW with a score out of 100 and forecast
Meyka AI rates ROG.SW with a score out of 100 at 69.32 (Grade: B, Suggestion: HOLD). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a monthly target CHF 374.99, a quarterly CHF 284.39 and a yearly CHF 244.76. The monthly projection implies upside 10.85% versus current price CHF 338.30, while the yearly model implies downside 27.65%. Forecasts are model-based projections and not guarantees.
Risks and opportunities for ROG.SW stock
Opportunity: Roches diagnostics franchise and late-stage oncology pipeline support steady cash flow and above-peer free cash flow yield 0.04555. Risk: margin pressure in pharma, high valuation multiples (PB 9.71) and sensitivity to regulatory outcomes could amplify downside. Institutional liquidity and dividend policy reduce extreme volatility, but product approvals and pricing remain stock-specific catalysts.
Final Thoughts
ROG.SW stock closed the most active Swiss session on 30 Jan 2026 at CHF 338.30 with volume 1489237.00, reflecting elevated trader interest in a defensive healthcare leader. Valuation is mixed: a PE 29.56 and price-to-book near 9.71 point to premium pricing, while free cash flow and a 2.80% dividend provide income support. Technicals show momentum but warn of overbought readings. Meyka AI’s forecast model projects monthly CHF 374.99 (implied upside 10.85%) and yearly CHF 244.76 (implied downside 27.65%); these scenarios highlight divergence between short-term momentum and longer-term mean reversion. Investors should weigh Roches strong diagnostics cash flow and pipeline against valuation and regulatory risks. Meyka AI, our AI-powered market analysis platform, flags a B / HOLD grade and recommends monitoring upcoming clinical readouts and sector flows before increasing exposure. Forecasts are model-based projections and not guarantees.
FAQs
What is the current price and trading volume for ROG.SW stock?
ROG.SW stock closed at CHF 338.30 on 30 Jan 2026 with volume 1489237.00, above the average volume 1141438.00, making it one of the most active names on SIX that day.
How does Meyka AI rate ROG.SW stock and what does that mean?
Meyka AI rates ROG.SW with a score of 69.32 (Grade B, Suggestion HOLD). The grade blends benchmark, sector, financial growth and forecasts and is informational, not investment advice.
What are the main valuation metrics for ROG.SW stock?
Key metrics: PE 29.56, EPS 11.74, PB 9.71, free cash flow yield 0.04555, dividend per share 9.70. These show premium valuation paired with solid cash generation.
What price targets does Meyka AI forecast for ROG.SW stock?
Meyka AI’s forecast model projects monthly CHF 374.99, quarterly CHF 284.39, and yearly CHF 244.76. These are model outputs and not guarantees; they show short-term upside but longer-term downside risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
